TMT1B and breast cancer: Our results confirmed that ASC-exos promoted the TOX, CD4, and LYZ1 expression and inhibited the Mettl7b and Serpinb2 expression in breast cancer tumors, which were significantly enriched in the Human T-cell leukemia virus 1 infection pathway.